Synonyms: LY2606368
Compound class:
Synthetic organic
Comment: Prexasertib (LY2606368), an investigational small molecule checkpoint kinase 1 (CHK1) inhibitor [2] that exhibits anti-tumour activity in preclinical models of pediatric cancer.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
Clinical development of prexasertib includes a phase 1 trial in pediatric solid tumors (NCT02808650). |
Mechanism Of Action and Pharmacodynamic Effects |
Inhibition of CHK1 disrupts the DNA damage response, resulting in the accumulation of DNA damage and eventual cell death. |